Publication Date:
2019
Description:
Abstract
We present the distribution of CYP2D6, CYP2C9 and CYP2C19 variants and predicted phenotypes in 33 native and admixed populations from Ibero‐America (n〉6,000) in the context of genetic ancestry (n=3,387). Continental ancestries are the major determinants of frequencies of the increased‐activity allele CYP2C19*17 and CYP2C19 gUMs (negatively associated with Native American ancestry), decreased‐activity alleles CYP2D6*41 and CYP2C9*2 (positively associated with European ancestry), and decreased‐activity alleles CYP2D6*17 and CYP2D6*29 (positively associated with African ancestry). For the rare alleles CYP2C9*2 and CYPC19*17, European admixture accounts for their presence in Native American populations, but rare alleles CYP2D6*5 (null‐activity), CYP2D6‐multiplication alleles (increased activity) and CYP2C9*3 (decreased‐activity) were present in the pre‐Columbian Americas. The study of a broad spectrum of Native American populations from different ethno‐linguistic groups shows how autochthonous diversity shaped the distribution of pharmaco‐alleles and give insights on the prevalence of clinically relevant phenotypes associated with drugs such as paroxetine, tamoxifen, warfarin and clopidogrel.
This article is protected by copyright. All rights reserved.
Print ISSN:
0009-9236
Electronic ISSN:
1532-6535
Topics:
Chemistry and Pharmacology
,
Medicine
Permalink